Atherosclerosis is a chronic inflammatory disease, in which the immune system has a
prominent role in its development and progression. Inflammation-induced endothelial …

Low-grade inflammation is the hallmark of metabolic disorders such as obesity, type 2
diabetes and nonalcoholic fatty liver disease. Emerging evidence indicates that these …

Background Experimental and clinical data suggest that reducing inflammation without
affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory …

Inflammation is an important driver of atherosclerosis, the underlying pathology of
cardiovascular diseases. Therefore, therapeutic targeting of inflammatory pathways is …

Background Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces
inflammation and cardiovascular event rates with no effect on lipid concentrations. However …

Systemic vascular inflammation plays multiple maladaptive roles which contribute to the
progression and destabilization of atherosclerotic cardiovascular disease (ASCVD). These …

Atherosclerosis is one type of cardiovascular disease (CVD) in which activation of the
NLRP3 inflammasome and toll-like receptor (TLR) pathways is implicated. One of the most …

Plasma levels of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP)
predict vascular risk with an effect estimate as large as that of total or high-density …

Background For several cardiometabolic risk factors, values considered within normal range
are associated with an increased risk of cardiovascular morbidity and mortality. We aimed to …

Inflammatory processes are firmly established as central to the development and
complications of cardiovascular diseases. Elevated levels of inflammatory markers have …